Article

Ptosis: A sign of myasthenia gravis

Ptosis is a sign of a number of diseases, most of which are benign. Julie Falardeau, MD, of the Casey Eye Institute, Portland, OR, described how ophthalmologists can avoid overlooking myasthenia gravis, which can be associated with serious morbidity and mortality.

Ptosis is a sign of a number of diseases, most of which are benign. Julie Falardeau, MD, of the Casey Eye Institute, Portland, OR, described how ophthalmologists can avoid overlooking myasthenia gravis, which can be associated with serious morbidity and mortality.

"It is important to be aware of myasthenia gravis because, as an ophthalmologist, you will be the one to examine that patient with ptosis," she said.

"Myasthenia gravis has ocular signs in about 75% of cases and the ocular signs are the first manifestations in over 90% of patients," she said.

Eighty-five percent to 90% of these patients will have systemic symptoms within 2 years, which underscores the importance of making an early diagnosis and referring to a neuro-ophthalmologist or neurologist, Dr. Falardeau said.

The hallmark of myasthenia gravis is variability of symptoms and fatigue. The ptosis, which can be unilateral or bilateral, usually increases as the day progresses in these patients but can be induced in a clinical setting by having the patients gaze upward for an extended period. She advised looking for a Cogan lid twitch, which is often present. When these patients are asked to gaze downward and then rapidly upward, a subtle overshoot of the lid, the Cogan lid twitch, may be seen.

The sleep test, the ice test, the Tensilon test and prostigmin also can assist in establishing a diagnosis of myasthenia gravis.

Dr. Falardeau urged ophthalmologists to conduct a comprehensive evaluation of patients who present with ptosis and to include myasthenia gravis in the differential diagnosis.

"Myasthenia is a serious urgent condition," she concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.